News >

Expert Highlights Latest Immunotherapy Efforts in CRC

Brandon Scalea
Published: Thursday, Aug 23, 2018

Michael J. Overman, MD
Michael J. Overman, MD
The role of checkpoint inhibitors in regulating host immune response to cancer has provided practice-changing therapeutic targets for clinicians. This has significantly shaped the treatment landscape in colorectal cancer (CRC), but much work remains for certain subtypes, particularly the microsatellite stable (MSS) patient population, said Michael J. Overman, MD.

, Overman, an associate professor in the Department of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center, discussed the current state of immunotherapy in patients with CRC and how to optimally manage immune-related adverse events.

OncLive: How has the rise of immunotherapy impacted patients with CRC?

Overman: Fundamentally, we've identified a subset within colon cancer that is very immune-responsive. For that subset, we have generated 3 different approvals for immunotherapy. In part, this was based on nonrandomized studies because for that subset, this kind of treatment works tremendously well. It's been a real success because, generally, we give therapy to everyone and it works in a small fraction of people. That has sort of been the normal cancer paradigm.

Here, we actually have a biomarker, MSI-H, which identifies a small group of patients where immunotherapy works great. Our data show that it works in over 50% of these patients. These responses aren't just durable, they're dramatic and could even be curable. For the other patient population, immunotherapy doesn't seem to work. Therefore, we have a really effective biomarker here. If you understand colorectal biology and understand the different subsets, then you can find a biomarker that separates a unique biology and is in tune with that. That is really the landscape right now. 

Immunotherapy comes with new toxicity complications. What steps are being taken to manage those?

Immunotherapy toxicities are very different from those related to systemic chemotherapy. In gastrointestinal (GI) cancers, the first approval was in CRC—this dMMR group—and this was the first immunotherapy experience we had. People who treat melanoma or lung cancer have had more experience with immunotherapy toxicity because these approvals have been in place for a little while now.

First off, there's no doubt that it takes time to get familiar with and used to these new toxicities. The steps are appreciation, diagnosis, and treatment. For the GI cancer space, this is all new to us. The key points are we need to have a heightened awareness of the symptoms with our patients and make sure they're communicating with us. The challenge is that, in the past, when people were treated with chemotherapy, they got sick with a fever, infection, or dehydration. Now, it's a little different. It's a cough with no fever, but it eventually turns into pneumonitis. It's diarrhea without a fever that turns into colitis. It's lack of energy in a patient that turns out to be pituitary dysfunction.


... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x